Source comparison
BPC-157 for Intestinal Permeability: Research vs Clinical Protocols
Dosage Range 10–20 mcg/kg twice daily (subcutaneous) 700–1400 mcg/day for 70 kg adult No Phase III human trials. Dosing extrapolated from animal allometric scaling Administration Route Subcutaneous or intraperitoneal injection Subcutaneous preferred; oral bioa
This comparison does not assign a generated winner or score.
- Dosage Range
- 10–20 mcg/kg twice daily (subcutaneous)
- 700–1400 mcg/day for 70 kg adult
- No Phase III human trials. Dosing extrapolated from animal allometric scaling
- Administration Route
- Subcutaneous or intraperitoneal injection
- Subcutaneous preferred; oral bioavailability unconfirmed
- Oral formulations lack pharmacokinetic validation in humans
- Treatment Duration
- 7–14 days in acute injury models; 28+ days in chronic inflammation
- Minimum 21–28 days for measurable tight junction protein upregulation
- Long-term safety data (>90 days) not established in humans
- Primary Endpoint
- Histological tight junction integrity scores; zonulin immunostaining
- Lactulose-mannitol ratio; serum zonulin levels; symptom resolution
- Symptom improvement doesn't confirm structural barrier repair
- Mechanism Confirmation
- Direct immunofluorescence of claudin/occludin expression
- Indirect. Serum biomarkers (zonulin, LPS) infer barrier status
- Intestinal biopsy required for definitive tight junction assessment
- Professional Assessment
- Consistent efficacy in chemically induced colitis and NSAID enteropathy models; mechanism confirmed through protein expression analysis
- Promising but extrapolated. Human data limited to case reports and observational series without placebo controls